Novartis signs $7.8 billion Abogen RNA deal
Share
Novartis (NYSE:NVS) signed a licensing and option agreement with privately held Abogen Biosciences worth up to about $7.8 billion for ABO2203 and other potential RNA-based programs.
Novartis (NYSE:NVS) signed a licensing and option agreement with privately held Abogen Biosciences worth up to about $7.8 billion for ABO2203 and other potential RNA-based programs.
On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
Novartis (NYSE:NVS) reported Q2 2026 net sales of $14.41 billion, up 3% in dollars and 1% at constant currencies.
Novartis (NYSE:NVS) reported fourth-quarter adjusted earnings that beat analyst estimates on Wednesday, but the Swiss pharmaceutical giant issued a cautious 2026 outlook as it prepares to navigate the largest wave of patent expirations in its history.
Novartis (NYSE:NVS) reported positive Phase 3 REMODEL-1 and REMODEL-2 trial results showing remibrutinib reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.
